Pre-clinical assessment of anti-vascular drugs using quantitative dynamic contrast-enhanced MRI

I Linnik, S R Williams, Karen E Davies, A T McGown, J A Hadfield, D L Buckley

Research output: Contribution to journalArticlepeer-review

Abstract

The effect of novel anti-cancer agents on the vascular properties of radiation-induced fibrosarcomas in C3H-strain mice was evaluated in vivo using dynamic contrast-enhanced (DCE) MRI. A T 1 -weighted volume acquisition was used to obtain DCE-MRI data. Pre-contrast T 1 measurements and the contrast agent arterial input function were used to estimate the volume transfer constant (K trans ) and extravascular extracellular volume fraction (v e ). Five novel combretastatin analogues, combretastatin A-4 (CA-4) and hazelnut oil (vehicle) were tested for their effect 24 hours after administration on the tumours. Three of the five agents and the positive control (CA-4), significantly decreased tumour K trans and v e : K trans for CA-4 by 72%; fluorocombretastatin by 75%; methylcombretastatin by 68%; and v e by 40% for methylcombretastatin and 75% for the combretastatin quinone. These agents were recommended for further consideration. These results suggest that DCE-MRI may be a useful tool for pre-clinical evaluation of anti-cancer drugs.
Original languageEnglish
Pages (from-to)326-372
Number of pages47
JournalInternational Journal of Medical Engineering and Informatics
Volume4
Issue number4
DOIs
Publication statusPublished - 2012

Fingerprint

Dive into the research topics of 'Pre-clinical assessment of anti-vascular drugs using quantitative dynamic contrast-enhanced MRI'. Together they form a unique fingerprint.

Cite this